Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
McKinsey
Federal Trade Commission
Merck
Chinese Patent Office
US Army
QuintilesIMS
Accenture
Healthtrust
Express Scripts

Generated: August 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Treatment of symptoms associated with premenstrual disorders
Abstract:There is disclosed a method for treating certain psychiatric symptoms including anger, rejection sensitivity and a lack of mental or physical energy with administration of a nontoxic dose of a serotonin re-uptake blocker. Preferably, the serotonin re-uptake blocker is fluoxetine or norfluoxetine.
Inventor(s): Norden; Michael J. (Seattle, WA)
Assignee:
Application Number:08/715,992
Patent Claims: 1. A method for treating psychiatric symptoms comprising administering a nontoxic dose of a serotonin re-uptake blocker to a patient, wherein the psychiatric symptoms are selected from the group consisting of anger, rejection sensitivity, and lack of mental or physical energy.

2. The method of claim 1 wherein the serotonin re-uptake blocker is seleted from the group consisting of fluoxetine, zimelidine, fluvoxamine, sertaline, indalpine, citalopram, femoxetine, paroxetine, alaproclate, and pharmaceutically acceptable salts thereof.

3. The method of claim 2 wherein the serotonin re-uptake blocker is fluoxetine or sertraline.

4. The method of claim 3 wherein the daily adult dose of fluoxetine is from about 2 mg to about 80 mg.

5. A method for treating psychiatric symptoms associated with premenstrual disorders, comprising administering a nontoxic dose of a serotonin re-uptake blocker to a patient, wherein the psychiatric symptoms associated with premenstrual disorders are selected from the group consisting of anger, rejection sensitivity, and lack of mental or physical energy.

6. The method of claim 5 wherein the serotonin re-uptake blocker is seleted from the group consisting of fluoxetine, norfluoxetine, zimelidine, fluvoxamine, sertraline, indalpine, citalopram, femoxetine, paroxetine, alaproclate, and pharmaceutically acceptable salts thereof.

7. The method of claim 6 wherein the serotonin re-uptake blocker is fluoxetine or sertraline.

8. The method of claim 7 wherein the daily adult dose of fluoxetine is from about 2 mg to about 80 mg.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
US Department of Justice
Express Scripts
Fuji
Teva
Novartis
Argus Health
Julphar
Queensland Health
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot